VivaMed BioPharma Enters into Partnership with Syngene International to Strengthen AI-driven Drug Repurposing Programmes
Friday, February 20, 2026
VivaMed BioPharma has entered into a strategic partnership with Syngene International to support the development and validation of therapeutic programmes identified through artificial intelligence (AI).
The collaboration is aimed at strengthening VivaMed’s global validation infrastructure and advancing repurposed drug candidates towards clinical readiness.
The collaboration focuses on aligning AI-led discovery with robust laboratory execution. By combining VivaMed’s data-driven hypotheses with Syngene’s experience in preclinical research and development, the partners aim to improve the scientific reliability, reproducibility, and regulatory preparedness of repurposed drug programmes.
VivaMed’s approach is built around a three-part development model designed to be compatible with pharmaceutical partnerships.
The first element is AI-powered discovery. VivaMed’s proprietary AI platform analyses large, multi-omic datasets to identify biomarkers, drug–disease relationships, and promising repurposing opportunities at scale, supported by a global network of scientific collaborators.
The second element is rigorous validation. Through the partnership with Syngene, VivaMed will expand its experimental framework to include in vitro and in vivo pharmacology studies, biomarker verification, assay development, pathway analysis, translational study design, and broader preclinical development support. This structured process is intended to strengthen intellectual property positioning and improve readiness for later-stage development.
The third element is strategic commercialisation. VivaMed plans to align validated programmes with pharmaceutical partner needs, using established regulatory routes such as the 505(b)(2) pathway and biomarker-led strategies to reduce development risk and improve scalability.
The partnership with Syngene forms part of VivaMed’s wider strategy to create an integrated, AI-enabled drug development ecosystem. By combining computational prioritisation with established contract research and development capabilities, the company aims to build a repeatable and partnership-ready development model.
Rather than operating as a closed discovery platform, VivaMed is expanding its network to include contract research organisations, academic groups, and pharmaceutical companies that follow a translational and execution-focused approach.
VivaMed continues to engage with potential partners interested in experimentally validated programmes, structured repurposing opportunities with intellectual property protection, biomarker-driven development strategies, and efficient ways to expand pipelines with reduced risk.
Through collaborations such as this, VivaMed aims to deliver therapeutic assets that are both scientifically sound and operationally aligned with current pharmaceutical development practices.
Source: businesswire.com
